TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03282344
Drug: NKTR-214
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
Study: NCT03745638
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study: NCT00584532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 Placebo Capsules taken orally every day.
Study: NCT00626886
Drug: placebo collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: collagen
Study: NCT00006101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take placebo per day for 12 months
Study: NCT01318031
Drug: Period 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
Study: NCT01318031
Drug: Period 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
Study: NCT02168010
Drug: Neurotropin
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic drug as positive control
Study: NCT01308255
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
Study: NCT02168010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank tablet as placebo.
Study: NCT00620828
Drug: Ropivicaine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivicaine
Study: NCT01428180
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
Study: NCT01428180
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
Study: NCT02864849
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02857478
Drug: BAY 987519, SPF 50, Y51-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
Study: NCT02857478
Drug: BAY 987519, SPF 50, P04-147
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
Study: NCT00732147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 micrograms given subcutaneously before each meal x 3.
Study: NCT02674113
Drug: regional anesthesia placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
Study: NCT00206947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
Study: NCT03775824
Drug: MTX start
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
Study: NCT02147873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080834
Drug: DJ-927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01358357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-80 mg flexible dose
Study: NCT01452607
Drug: SPI-1005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Ebselen oral capsules (SPI-1005), single dose
Study: NCT01452607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Ebselen oral capsules (SPI-1000), single dose
Study: NCT02473354
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
Study: NCT00976716
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily
Study: NCT00763347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT00694759
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule twice daily
Study: NCT00923351
Drug: Tumor Purged/CD25 Depleted Lymphocytes
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00974012
Drug: Depakote®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ER Tablet
Study: NCT04357015
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
Study: NCT01169701
Drug: Mycophenolic acid (MPA)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
Study: NCT02655757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo,1 tablet per day for 12 months
Study: NCT00153595
Drug: EWO1
Normalized name: Ethinyl Estradiol and Norgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00651014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
Study: NCT04643587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl)
Study: NCT01103609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet bd, stepwise increased
Study: NCT01103609
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet bd, stepwise increased
Study: NCT01536314
Drug: Placebo : lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
Study: NCT03930446
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
Study: NCT02291055
Drug: ADXS11-001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02291055
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00077103
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin IV over 5-10 minutes
Study: NCT01290146
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
Study: NCT01828892
Drug: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
Study: NCT02567799
Drug: BIO 300 Oral Suspension
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
Study: NCT03309358
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
Study: NCT01541137
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
Study: NCT01541137
Drug: parecoxib/ valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
Study: NCT04546347
Drug: AZD9833 film-coated tablet A Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 AZD9833 film-coated tablet A Dose 1
Study: NCT04546347
Drug: AZD9833 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9833 Oral Solution
Study: NCT04546347
Drug: AZD9833 film-coated tablet A Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 of AZD9833 film-coated tablet A Dose 2
Study: NCT01978028
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03089203
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2/day given over 3 days
Study: NCT01536379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study: NCT01984008
Drug: Picosulfate sodium, magnesium oxide, citric acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00846755
Drug: Levothyroxine, Propylthiouracile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs were titrated to render euthyroid pregnant patients with thyroid disease
Study: NCT02071355
Drug: TMC435 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
Study: NCT02071355
Drug: TMC435 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
Study: NCT04991181
Drug: 400 mg BIA 5-1058
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
Study: NCT00312494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with mood stabilizer (either lithium or divalproex)
Study: NCT01862887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, PH-797804 matched placebo, single dose
Study: NCT03669835
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
Study: NCT02187588
Drug: Eschscholtzia Californica - low dose
Normalized name: Eschscholzia californica extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02187588
Drug: Eschscholtzia Californica - high dose
Normalized name: Eschscholzia californica extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02187588
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02187588
Drug: Eschscholtzia Californica - low dose Placebo
Normalized name: Eschscholzia californica extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02187588
Drug: Eschscholtzia Californica - high dose Placebo
Normalized name: Eschscholzia californica extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02187588
Drug: Ibuprofen Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00009048
Drug: IV Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03160833
Drug: HMPL-453
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administrative
Study: NCT00422266
Drug: Omega 3 fatty acids and plant sterol enriched drink
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03121092
Drug: ACEI or ARB
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
Study: NCT03989440
Drug: AXER-204
Approvals — FDA: no, EMA: no, PMDA: no
Description: human NoGo Trap fusion protein
Study: NCT03989440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline formulation
Study: NCT02369081
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
Study: NCT03878914
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
Study: NCT02207790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
Study: NCT01210365
Drug: Diurisa®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
Study: NCT01210365
Drug: Lasix ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
Study: NCT00873509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
Study: NCT02369081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 12 weeks.
Study: NCT00465972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule nightly for duration of study
Study: NCT02784821
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
Study: NCT01139450
Drug: 0417
Normalized name: estradiol 0.00417 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0417 test product applied twice daily for 4 weeks
Study: NCT01139450
Drug: Vehicle of 0417 test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of 0417 test product applied twice daily for 4 weeks
Study: NCT01517009
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
Study: NCT01277523
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations once daily
Study: NCT04608500
Drug: FMX103 minocycline foam 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study: NCT02695745
Drug: Celecoxib capsules
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg (2 capsules of 200 mg each) taken orally x 1 dose
Study: NCT02695745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
Study: NCT00919776
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 40mg daily then reducing regimen over 16 weeks
Study: NCT01899638
Drug: UMEC/VI 125/25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination in high dose
Study: NCT01899638
Drug: UMEC/VI 62.5/25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination in low dose
Study: NCT01899638
Drug: UMEC 62.5 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMA mono in low dose
Study: NCT01899638
Drug: VI 25 mcg
Normalized name: Typhim VI 25 MCG per 0.5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA mono
Study: NCT02670655
Drug: MAL application
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
Study: NCT01157507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single injection of placebo
Study: NCT00174915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, once daily for up to 28 weeks.
Study: NCT00642707
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03295981
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
Study: NCT00112502
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg orally twice a day continuous dosing
Study: NCT04312477
Drug: Modified Gegen Qinlian Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
Study: NCT01941927
Drug: GSK2141795
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
Study: NCT02130674
Drug: Dipeptiven
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
Study: NCT02648009
Drug: Hyperpolarized (13) Pyruvate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI with Hyperpolarized Pyruvate (13) Injection
Study: NCT03873298
Drug: Inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
Study: NCT03617718
Drug: Glycine Buffer
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
Study: NCT00993863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00993863
Drug: ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose
Study: NCT01941654
Drug: Oral TKI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00593177
Drug: PTH (1-34) Gel / Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dosing of gel twice daily for eight weeks.
Study: NCT03303053
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
Study: NCT03303053
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
Study: NCT02608268
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-human PD-1 monoclonal antibody. PDR001 administered via intravenous (i.v.) infusion either every 2 weeks (Q2W) or every 4 weeks (Q4W).